ADIPOQ and metabolic dysfunction-associated steatohepatitis: With this more in‐depth novel approach we conducted a post‐hoc analysis of subjects with biopsy‐proven NASH randomized to either pioglitazone or placebo treatment for 6 months to study the individual and combined impact of changes in fat distribution (SC vs VF), adipose tissue IR, and plasma adiponectin (ADPN) concentration, relative to the improvement in disease activity on histology in patients with NASH.